Jim Cramer recently highlighted Eli Lilly and Company (LLY) as a standout example of corporate efficiency, praising its ability to build a factory in record time. The factory, located in Concord, ...

Eli Lilly has raised its revenue guidance ... In its update, Ricks said a new facility at Concord in North Carolina – part of an $18 billion investment programme launched in 2020 – is being ...

Some of the potential iterations of delivery methods Eli Lilly considered ... and building four new Lilly manufacturing facilities in the U.S., including in North Carolina, Wisconsin, and ...

Eli Lilly has followed Novo Nordisk in announcing ... with investment projects ongoing in North Carolina and Indiana in the US. The new facility in Germany is preparing for the future, however ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes. By Rebecca Robbins and Gina Kolata Encouraging ...

Eli Lilly announced a successful Phase 3 clinical trial of its new GLP-1 weight loss drug, orforglipron, which comes in pill form -- not an injection. This first trial showed weight loss of 7.9% ...

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY). In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer ...

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership in obesity treatment. Orforglipron offers advantages ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 15.3% in the morning session after results from a Phase 3 trial showed that its experimental drug, Orforglipron, performed ...

Eli Lilly shares jumped 15% after a clinical trial of its experimental pill showed it helped patients with Type 2 diabetes lose weight at levels comparable to leading injectable medications like ...

Orforglipron, an experimental treatment Eli Lilly is developing for diabetes and weight loss, hit high marks in the first of several pivotal trials. The daily tablet produced blood-sugar ...